Abstract Radiolabeled Pittsburgh compound B (PIB)
Introduction
Radiolabeled Pittsburgh compound B (PIB; [N-methyl- promising in vivo imaging agent that can bind with high affinity, specificity, and stoichiometry to parenchymal amyloid-b deposits [13, 23, 30] and cerebral b-amyloid angiopathy (CAA) [2, 11] in patients with Alzheimer's disease (AD). Positron-emission tomography (PET) imaging studies indicate that 11 C-labeled PIB rapidly enters the brain, where it is retained significantly longer in Ab-rich regions than in brain areas that lack Ab deposits [13, 23] . Thus, PIB is a promising tool for the early diagnosis of AD plaque pathology in living patients [21, 24] .
Evaluation of postmortem or biopsied brain samples from patients who exhibited cortical PIB retention in PET scans indicates that PIB binding in vivo correlates with heavy cerebral Ab deposition [2, 10, 16] . However, some instances of unexpectedly high uptake in nondemented cases [30] , or unexpectedly low retention in clinically diagnosed AD cases [5, 13, 18, 22] , have been reported, and some Ab lesions appear to be refractory to PIB binding [10, 31] . Studies in vitro and in animal models furnish additional evidence that, at nanomolar concentrations similar to those achieved in PET imaging, PIB does not bind to all multimeric assemblies of Ab equally [14, 29, 31] . Specifically, the density of highaffinity PIB binding sites per molecule of Ab is much lower in b-amyloid precursor protein (APP)-transgenic mice [14] and in normal aged nonhuman primates [29] compared to AD patients, despite profuse cerebral Ab deposition in the animal models.
These experiments suggest that PIB may recognize a polymorphic molecular site on multimeric Ab that is enriched in human AD cases but is altered or concealed in nonhuman species [17, 29] . The occasionally weak correlations between PIB binding and Ab levels [5, 13, 18, 22, 29, 30] and the presence of poorly binding lesions in some brain regions [10, 31] suggest the possible existence of polymorphic Ab aggregates in humans as well. Here, we report a case of clinically and pathologically confirmed AD with heavy Ab burden yet strikingly reduced high-affinity PIB binding in vitro compared to a series of nine other AD cases. This finding raises the possibility that some cases of clinicopathologically verifiable AD might not show significant retention of radiolabeled PIB in diagnostic PET scans, and further suggests that PIB can discriminate among naturally-occurring, polymorphic forms of multimeric Ab in humans.
Materials and methods

Subject
A 72-year-old woman (case AD1) came to autopsy with a diagnosis of probable Alzheimer's disease. Ten years earlier she had presented with impairments in short-term memory and visuospatial function. Both began insidiously and slowly worsened with time, and were followed approximately 4 years later by slowing of gait and increasingly frequent urinary incontinence. She experienced a gradual worsening of cognition in the subsequent years, in addition to worsening gait disturbance and incontinence. Nine years after her initial symptoms, she underwent ventriculo-peritoneal shunt placement for possible normal pressure hydrocephalus. Her family reported transient improvement in her gait and incontinence, which then regressed within 1 month of the shunt placement, likely due to shunt malfunction. Subsequent shunt revisions did not improve her symptoms, and she died shortly thereafter. Aside from her mother, who had Parkinson's disease but normal cognition, she had no known family history of dementia or other neurodegenerative diseases.
At autopsy, the brain weighed 1,110 g and showed no significant atrophy over the convexity. Vessels of the circle of Willis showed mild-to-moderate, patchy atherosclerosis with 50% occlusion of the right middle cerebral artery. A lesion approximately 1 cm in diameter was noted in the right frontal cortex corresponding to the site of entry of the ventricular shunt, and an old infarct approximately 1.5 cm in diameter was identified in the right medial posterior parieto-occipital cortex. The lateral and third ventricles were markedly dilated, and the hippocampus, amygdala and entorhinal cortex showed moderate atrophy. The caudate nucleus was slightly flattened, but the substantia nigra was normally pigmented. Histopathologically, the case was assigned a Braak AD stage of 6 (Table 1) ; the apolipoprotein E genotype was ApoE3/4.
Comparison subjects
Nine additional, clinically and pathologically confirmed AD cases and three age-matched, nondemented subjects were analyzed for comparison with AD1 (Table 1) in the core analysis. These subjects were part of an earlier comparative study of Ab in humans and nonhuman primates [29] . Tissue samples from three additional clinically and pathologically confirmed AD cases (which were verified to be PIB-sensitive by in vitro 3 H-PIB binding analysis) and one age-matched control (Table 1) were used as comparison subjects only in the MALDI-TOF mass spectrometry analyses (below).
Tissue preparation
Bilateral tissue slabs from the core subjects were dissected from the superior temporal gyrus (AD, n = 10; ND, n = 3) and the paracalcarine occipital cortex (AD, n = 7; ND, n = 3). The samples from one hemisphere were quickly frozen and stored at -80°C. Frozen tissue was later weighed and Dounce-homogenized in five volumes of Trisbuffered saline (TBS) homogenization buffer (50 mM TrisHCl and 150 mM NaCl containing complete protease inhibitor [Santa Cruz Biochemicals, Santa Cruz, CA, USA]). Aliquots of the homogenates were stored at -80°C until use in the PIB binding analysis, Ab-ELISAs, immunoblots and mass spectrometry. Additional blocks of frozen tissue were sectioned at 10 lm on a cryostat and mounted onto silanized slides (Fisher Scientific, Waltham, MA, USA). Location-matched tissue from the contralateral hemisphere was fixed in phosphate-buffered, 4% paraformaldehyde, embedded in paraffin wax, and processed for histochemical analysis. In two AD cases, fixed, nonembedded samples from the temporal neocortex were used for ultrastructural investigation (below). All tissue samples were obtained from the Emory University Alzheimer's Disease Research Center Brain Bank and the Sun Health Research Institute Brain Bank (Sun City, AZ), in accordance with federal and institutional guidelines, and the samples were coded to ensure the anonymity of the subjects.
DNA sequencing for b-amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2)
Coding exons 3-18 with the corresponding 50 bp of intronic junctions of APP and all coding exons from both PSEN1 and PSEN2, along with at least 25 bp of flanking sequence, were sequenced from genomic DNA extracted from AD1 brain tissue, using primers described in the supplementary material (Tables S1, S2 and S3).
Immunohistochemistry
Tissue sections from all AD cases were processed immunohistochemically using monoclonal anti-Ab antibodies 6E10 to Ab1-16 (1:25,000), 4G8 to Ab17-24 (1:5,000; both from Covance, Princeton, NJ, USA), and 8E1 to the pyroglutamized amino terminus of Ab pyr-glu 3-x (1:5,000; Immuno-Biological Laboratories, Gunma, Japan); polyclonal antibodies R361 to Ab32-40 and R398 to Ab33-42 (both at 1:15,000, courtesy of Pankaj Mehta, Institute for Basic Research on Developmental Disabilities, Staten Island, NY, USA); monoclonal anti-tau antibodies CP13 to phosphorylated tau serine 202 (1:10,000), MC1 to a pathologic conformation of tau (1:5,000; both courtesy of Peter Davies, Albert Einstein College of Medicine, Bronx, NY, USA), and AT8 to phosphorylated tau serine 202/phosphothreonine 205 (1:5,000; Covance). To rule out the presence of synucleinopathy, we employed a polyclonal antibody to a-synuclein (1:300, courtesy of Bernardino Ghetti, Indiana University, Indianapolis, IN, USA) (see Rosen et al. [28] for antibody details).
Vectastain Elite kits (Vector Laboratories, Burlingame, CA, USA) were used for avidin-biotin complex (ABC)/ horseradish peroxidase immunodetection of antigen-antibody complexes, with diaminobenzidine (DAB) or DAB ? nickel as chromogens. Appropriate positive control specimens from cases with previously confirmed pathology were included in all immunostaining experiments. In some instances, sections were lightly counterstained with hematoxylin. Non-immune mouse IgG or rabbit serum was used in place of the monoclonal and polyclonal primary antibodies, respectively, as negative controls. Some additional sections were stained with Congo Red, Thioflavin-T, hematoxylin and eosin, or the Campbell-Gallyas AD-silver stain [29] .
Electron microscopy
Fixed tissue slabs from the temporal neocortex of two AD cases (the PIB-refractory case [AD1] and a PIB-sensitive case [AD6]) were cut on a vibratome at 70-lm thickness, and regions of heavy Ab load were identified in adjoining sections immunostained with antibody 6E10. Samples from these regions were dissected from the adjacent, nonimmunostained section, washed in phosphate buffer (0.1 M, pH 7.4) and immersed in osmium tetroxide (1% in phosphate buffer) for 20 min. They were then rinsed in phosphate buffer and dehydrated in graded concentrations Ultrathin sections were cut with a Leica Ultracut T2 (Nussloch, Germany), collected onto single-slot copper grids, and stained with lead citrate. Thin sections were examined with a Zeiss EM10-C electron microscope (Oberkochen, Germany) and digital images were captured with a Dual View camera (Gatan Inc., Pleasanton, CA, USA).
H-PIB binding assay
To measure high-affinity PIB binding in cortical homogenates, all samples were simultaneously incubated with 1.0 nM 3 H-PIB (specific activity = 82 Ci/mmol, custom synthesis, GE Healthcare, UK) in a microplate radioligand binding assay [29] . At 1.0 nM, the concentration of free 3 H-PIB used in our in vitro experiments is comparable to that achieved with 11 C-PIB in PET scans [30] , and is selective for the high-affinity binding sites on Ab [2, 11, 12, 14] . The same tissue homogenates used in Ab ELISAs (below) were diluted 1:33.3 in phosphate-buffered saline (PBS) (pH 7.4) to a final concentration of 5-mg wet weight tissue/ml. In a 96 well polypropylene plate, 100 lg of wet cortical tissue (20 ll of diluted homogenate) from each sample was incubated, in duplicate, with 200 ll of 1.0 nM 3 H-PIB in 5% ethanol/PBS (nonspecific binding was defined as counts detected in the presence of 1.0 lM unlabeled PIB). After a 2.5-h incubation (at room temperature, without shaking), samples were quickly transferred to a 96 well Multiscreen HTS Hi Flow FB filter plate and filtered with a vacuum manifold (Millipore Corporation, Billerica, MA, USA). Filters were rinsed four times with PBS at room temperature. The filters were dried for 30 min at 37°C, after which 50 ll of MicroScint 20 (PerkinElmer, Waltham, MA, USA) scintillation fluid was added to each well and the plate was incubated at room temperature for 24 h, shaking at 100 rpm. 
H-PIB autoradiography
Slide-mounted, unfixed cryosections were brought to room temperature in air-tight containers and then immersionfixed in 10% ethanol/PBS for 20 min. Sections were incubated in 1.0 nM 3 H-PIB (specific activity = 82 Ci/ mmol) in 5% ethanol/PBS for 1 h at room temperature, rinsed twice with 10% ethanol/PBS and two times with ddH 2 O, both on ice, and then air-dried before exposing directly to a BAS-TR2040 tritium imaging plate (Fujifilm, Stamford, CT, USA). After 2 weeks of exposure, the plate was developed in a BAS-5000 Image Plate Scanner and images were captured with MultiGauge software (Fujifilm). Adjacent cryosections were immunostained with Ab antibody 6E10, as described above.
ELISA quantification of Ab40 and Ab42
Cortical homogenates were spun at 100,0009g for 1 h at 4°C in a TLA-100.4 ultracentrifuge rotor (Beckman Coulter, Fullerton, CA, USA). After collecting buffer-soluble supernatants, the pellet was sonicated in 70% formic acid, spun at 16,1009g for 60 min at 4°C, and the clear supernatant was collected as the buffer-insoluble extract. For both extracts, total Abx-40 and Abx-42 levels were measured by enzyme-linked immunosorbent assays (ELISA) using standardized kits (The Genetics Company, Schlieren, Switzerland) as previously described [28, 29] . Ab content is expressed relative to the wet weight of the tissue samples (Tables 2, 3 ).
Western blot
Unfixed cortical tissue blocks were Dounce-homogenized in four volumes of PBS. The 20% homogenate was vortexed, probe-sonicated 3 9 5 s (level 4, Model 100 ultrasonic dismembrator, Fisher Scientific), centrifuged at 3,0009g for 5 min at 4°C, and the supernatant was stored at -80°C until use. Total protein was quantified in the sample with a microplate bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL, USA). 60 lg of protein was boiled for 5 min in 29 Tricine sample buffer and 109 Reducing Agent (Invitrogen, Carlsbad, CA, USA), run on a 10-20% Tricine gel (Invitrogen) and blotted onto a nitrocellulose membrane. The membrane was boiled for 15 min in 19 PBS, then blocked at room temperature in 2.5% nonfat milk/0.05% Tween-20/TBS (blocking buffer) for 60 min, incubated in primary antibody to Ab (6E10, 1:1,000 diluted in blocking buffer) for 48 h at 4°C, followed by 90 min in horseradish peroxidase-conjugated anti-mouse IgG antibody (1:10,000 in blocking buffer, GE Healthcare, Piscataway, NJ, USA). Antibody binding was detected with Super Signal West Pico electrochemiluminescence substrate (Fisher Scientific) and exposed to Kodak MR Biomax film (Kodak, New Haven, CT, USA).
Immunoprecipitation/MALDI-TOF MS
For mass spectrometry, cortical homogenates were ultracentrifuged to isolate buffer-soluble Ab (see above). Pellets were homogenized in 2% SDS, spun at 100,0009g for 60 min at 10°C to extract detergent-soluble Ab, and the pellet containing detergent-insoluble proteins was sequentially extracted with 70 and 100% formic acid (above). Immunoprecipitation of Ab was performed using paramagnetic beads coated with a cocktail of antibodies 4G8 and 6E10, or C-terminal specific antibody 12F4 to Abx-42, and the precipitates analyzed by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry, as previously described [32] . Briefly, Dynal Table S4 ).
Histopathology
Immunohistochemically, subject AD1 had copious densecored and diffuse parenchymal senile plaques characteristic of advanced AD, as well as significant large vessel and capillary CAA and tau-positive neurofibrillary pathology (Figs. 1, 2 ). Parenchymal and vascular Ab lesions were detected throughout the temporal and occipital cortices of case AD1, with slightly more parenchymal deposits in the temporal cortex and a predilection for vascular amyloid deposition in occipital cortical regions (Figs. 1a, 2) . The presence of AD-typical lesions was confirmed by multiple antibodies to Ab and tau, and by the Congo Red, Thioflavin-T and Campbell-Gallyas silver stains (not shown). Antibody R398 to Ab42 disclosed a large variety of parenchymal and vascular lesions, similar to antibody 6E10, whereas antibody R361 to Ab40 labeled primarily CAA and plaque cores (Fig. 3) . Antibody 8E1 to Ab pyr-glu 3-x, like antibodies 6E10 and R398, stained a broad spectrum of vascular and parenchymal Ab deposits (not shown). Ultrastructurally, the senile plaques consisted of fibrillar material consistent with amyloid (Fig. 1c) , and the neurofibrillary pathology included filamentous ribbons typical of AD (Fig. 1d) . The antibody to a-synuclein did not show concomitant cortical Lewy bodies or Lewy neurites in this case (not shown).
H-PIB binding and Ab analysis
PIB binding was markedly reduced in temporal and occipital cortical homogenates of case AD1 compared to nine other clinically and pathologically confirmed AD subjects (Fig. 4) , and was in the range of the non-demented control cases (PIB also bound strongly to homogenates from the AD cases used as controls for the mass spectrometry analysis, below). Despite a paucity of highaffinity PIB binding sites, ELISAs disclosed levels of soluble and insoluble Ab40 and Ab42 that greatly exceeded those in both brain regions of all nine comparison AD cases in the core group (Tables 2, 3 ). The Ab40:Ab42 ratios for soluble and insoluble Ab also were higher in AD1 than in the nine other AD cases (Fig. 4) . A competition curve experiment with 3 H-PIB and unlabeled PIB in temporal cortical homogenates from AD1 and a comparison case (AD2) revealed a high-affinity PIB binding site in AD2 (Kd = 3.0 nM and Bmax = 290 fmol), comparable to previously published reports [10, 14, 29] , but not in AD1 (Fig. 5) . Similar results were seen in the occipital cortex (data not shown). Finally, mixing experiments with AD1 and AD2 temporal and occipital cortical homogenates revealed only an additive effect on PIB binding when equal parts of tissue from each case were mixed and incubated with 1.0 nM 3 H-PIB (Fig. 6 ). Autoradiography of 1 nM 3 H-PIB binding in unfixed cryosections revealed some cortical plaques in the superior temporal cortex of case AD1. However, comparison with an adjacent cryosection that was immunostained with antibody 6E10 indicated that only a subset of potential plaques and CAA was labeled (Fig. 7) . In the temporal cortex of a comparison AD subject (AD5), 3 H-PIB autoradiography and 6E10 immunohistochemistry on adjacent cryosections showed substantial overlap of Ab-immunoreactive and PIB-positive lesions (Fig. 7) . Using antibody 6E10 for Western blot analysis of temporal cortical extracts from AD1 and seven comparison AD cases, strong bands of 4KDa Ab monomers were detected in all eight cases. Faint bands corresponding to Ab dimers (*8 KDa) were detectable in several of the AD cases. In the cortical extract from AD1, however, these Ab dimer bands were of substantially greater intensity relative to the seven comparison AD cases, and a strong immunoreactive band was detected at *12 KDa, corresponding to trimeric Ab. Additionally, numerous higher molecular weight bands H-PIB reveal high levels of PIB binding to temporal and occipital cortical tissue from all AD cases in this study except AD1, which showed only background levels of PIB binding. d The ratio of PIB binding to total Ab in two cortical regions. When AD1 data points were excluded from the analysis, total levels of insoluble Ab (Ab40 and Ab42) correlate positively with migrating between 17 and 44 kDa were detected solely in AD1 temporal cortical tissue. APP levels (*100 KDa) were similar in AD1 and the seven comparison AD cases (Fig. 8) . Because our ELISA analyses indicate considerably higher total Ab levels in AD1 tissue, an immunoblot was conducted with AD1 cortical extract that was diluted to reduce total protein, thereby yielding total Ab levels that were comparable to the mean Ab levels in the comparison AD cases. When Ab levels are normalized as such, the higher molecular weight 6E10-immunoreactive bands, though weaker, are still visible (data not shown).
Ab MALDI-TOF mass spectrometry MALDI-TOF MS on immunoprecipitated buffer-soluble, SDS-soluble, and formic acid-soluble Ab from AD1, three comparison (PIB-sensitive) AD cases and one nondemented control case revealed a pattern of N-and Cterminally truncated fragments unique to AD1 temporal cortex (Fig. 9 , data from two AD cases and the nondemented case not shown). Full-length Ab40 and Ab42 were detected in all fractions from all AD cases, although Ab42 was barely detectable in AD1 buffer-soluble extract, suggesting that the peptide may be preferentially deposited in insoluble lesions and/or cleared from the brain (Fig. 9) . Numerous buffer-soluble, C-terminally truncated Ab fragments were identified in AD1 tissue (Ab1-38, Ab1-37, Ab1-36, Ab1-34, Ab1-33, Ab1-29, Ab1-28, Ab1-19, Ab1-18, Ab1-16) but not in any of the three comparison AD cases. Insoluble Abx-42 fragments with various N-terminal truncations were identified in the AD1 insoluble extract, as were oxidized Ab40, Ab42, and Abx-42 peptides, the majority of which were not seen in the comparison cases.
Discussion
Pittsburgh compound B has been shown to bind with high affinity to parenchymal senile plaques [13, 23, 30] and to cerebral b-amyloid angiopathy [2, 11] in Alzheimer's disease. Previous studies also have reported a significant positive correlation between PIB binding and Ab levels [2, 10, 16, 31] , further supporting the utility of this ligand in the antemortem diagnosis of AD and CAA. In assessing 3 H-PIB binding to cortical tissue homogenates in a series of ten AD patients, however, we discovered a case of pathologically confirmed AD (case AD1) with particularly heavy cerebral Ab deposition, yet negligible high-affinity binding of PIB.
To address potential reasons for the paucity of PIB binding in case AD1, we first considered the ways in which this patient differed from the other AD cases. Histopathologically, AD1 showed numerous diffuse parenchymal Ab H-PIB with 1:1 mixtures of cortical homogenates from a typical PIB-sensitive AD case (AD2) and the PIB-refractory case AD1. We did not identify an inhibitory or synergistic effect on PIB binding in either the temporal or occipital cortical homogenates. Rather, the quantity of PIB binding to mixed homogenates was approximately the sum of total PIB binding to each individual homogenate. Similar results were seen when 1.0 nM 3 H-PIB was incubated with mixtures of temporal and occipital cortical homogenates from AD2 and a nondemented control case (ND2) that alone exhibited negligible high-affinity PIB binding deposits, dense-cored Ab plaques and neurofibrillary tangles typical of advanced AD, as well as substantial large vessel and capillary CAA (Figs. 1, 2, 3, and 7) . However, relative to PIB-sensitive AD cases, autoradiography with 1 nM 3 H-PIB detected only a fraction of the senile plaques and CAA in AD1 (Fig. 7) . Comparison with the adjacent, Ab-immunostained sections did not indicate preferential binding of PIB to a particular type of Ab lesion. Although AD1 had substantial CAA, some degree of CAA is usual in AD [1] , and vascular amyloid was present (albeit to a lesser degree) in most of the other cases that we examined. Furthermore, PIB has been shown to be a sensitive marker for CAA in vivo [2, 11] and in vitro [19] . Finally, in addition to CAA, abundant dense and diffuse Ab plaques were present in the cortical samples from AD1 (Fig. 1) , yet, despite a heavy burden of Ab lesions of multiple types, high-affinity PIB binding was unexpectedly meager.
Next, we used ELISA to measure the overall quantity of Ab and found that the levels of both soluble and insoluble Ab40 and Ab42 in AD1 greatly exceeded those in the comparison group of nine AD patients. We then asked whether the relative amounts of Ab40 and Ab42 might influence PIB binding. As usual, for AD patients with prominent CAA [15, 27] , the Ab40:Ab42 ratio was particularly high in AD1 (temporal cortex: Ab40: Ab42 = 1.42 vs. 0.22 in the comparison AD group; occipital cortex: Ab40:Ab42 = 2.94 vs. 0.04 in the comparison group). However, PIB binding has been shown to correlate strongly with levels of both Ab40 and Ab42 in brain tissue [31] , and PIB also binds with low stoichiometry but equal affinity to synthetic, aggregated Ab40 and Ab42 in vitro [14] . Hence, neither a paucity of Ab nor the absolute amounts of the two major isoforms of Ab is a likely explanation for the deficiency of high-affinity PIB binding in this case. However, the influence of the ratio of Ab isoforms on PIB binding to Ab generated in vivo deserves further study.
To rule out the presence of a diffusible cortical element in case AD1 that specifically inhibits the high-affinity binding of PIB to Ab, we then incubated 3 H-PIB with mixtures of cortical homogenates from AD1 and a typical PIB-sensitive AD case (AD2). Both in temporal and occipital cortices, PIB binding to AD2 cortical homogenate was neither enhanced nor decreased in the presence of AD1 cortical homogenate, indicating an absence of diffusible factors in the AD1 cortex that inhibit high-affinity PIB binding to Ab. These data also argue against a diffusible substance in typical AD tissue that stimulates PIB binding to Ab, as the mixture of AD2 and AD1 cortical homogenates failed to increase PIB binding beyond the sum of the There is evidence to suggest that PIB binds with high affinity to parenchymal lesions containing N-terminallytruncated and modified Ab pyr-glu 3-x peptide isoforms, and that the low stoichiometry of PIB binding to Ab in the transgenic mouse brain may be attributable to a dearth of such modified Ab isoforms [8, 20] . In case AD1, however, an N-terminal-specific antibody to Ab pyr-glu 3-x labeled a substantial majority of parenchymal and vascular Ab deposits in the temporal and occipital cortices. By mass spectrometry of temporal cortical samples, we did identify a pattern of N-and C-terminally truncated Ab peptides unique to AD1:Ab1-x fragments predominated in the soluble extract, and Abx-42 peptides were detected mainly in the insoluble extract (Fig. 9) . The heterogeneity of C-terminal Ab fragments in the PIB-refractory case may represent the atypical action of carboxyl peptidase(s) in AD1 brain. The possibility of anomalous peptidase activity and/or Ab clearance mechanisms in this subject, as well as the effect of modified Ab isoforms on PIB binding affinity, remain to be established. Importantly, these data indicate that deficient high-affinity PIB binding to cortical homogenate from this case is not attributable to an absence of modified or truncated Ab isoforms that are generally found in mature plaques of the AD brain. Furthermore, in conjunction with the extract-mixing experiments (above), the findings suggest that the presence of abundant Ab1-x fragments in the soluble extract does not inhibit PIB binding when introduced into cortical extracts from other AD cases.
We then analyzed the distribution of multimeric Ab by SDS-PAGE/Western blot, and detected Ab monomers and dimers in both AD1 and most of the comparison AD cases. However, Ab immunoblots also yielded a dense series of low and higher molecular weight Ab-immunoreactive bands in AD1 that were not identified, under identical conditions, in any of the comparison AD cases (Fig. 8) . Normalization of total Ab levels indicated that these bands could not be attributed solely to the heavy Ab load in AD1. Whether these oligomers are indicative of an alternative Ab folding/aggregation pathway unique to this case, and whether the presence of these oligomers somehow inhibits PIB binding, warrants further investigation. Again, however, the absence of an inhibitory effect of AD1 extract on PIB binding in other AD cases (above) argues against the presence of such an inhibitory factor, at least in a readily diffusible form.
The E4 subtype of apolipoprotein E has been linked to an increased likelihood of developing both AD [4, 25] and CAA [7, 26] , and to the overall severity of cerebral bamyloidosis [9, 33, 34] . However, like AD1, seven of the nine AD cases in the comparison group also were hemizygous for ApoE4, and one was homozygous, yet all of these individuals displayed strong in vitro binding of 3 H-PIB, as did the case that was ApoE3/3. Consequently, apolipoprotein E genotype per se does not account for the anomalous PIB binding in AD1. Genetic analysis of the common AD-associated loci in the genes for APP, presenilin 1 and presenilin 2 revealed no obvious mutations or functional polymorphisms that might explain the paucity of high-affinity PIB binding in AD1.
Although the PIB-refractory AD case was not imaged with 11 C-PIB prior to death, our in vitro findings, using a concentration of free 3 H-PIB similar to that achieved in the brain parenchyma of 11 C-PIB-scanned patients [30] , suggest the possibility that the PET signal would have been diminished or absent in this patient, despite the presence of copious cerebral Ab. Currently, few cases of suspected AD have been imaged with PIB and then characterized pathologically and biochemically postmortem; consequently, the frequency of PIB-refractory cases in the AD population is unknown. Although there is compelling evidence that PIB binds only weakly to Ab deposits in nonhuman species [14, 29, 31] , our present results, in conjunction with other findings [5, 13, 18, 22] , suggest that PIB imaging may not detect all Ab lesions in some humans as well [5, 13, 18, 22] . Ab were detected in all AD cases examined. Faint bands corresponding to Ab dimers were detected only in some of the AD lanes under these conditions. In AD1, 6E10 immunoblotting revealed high levels of dimeric and trimeric Ab, as well as several higher molecular weight, Ab-immunoreactive bands between 17 and 44 KDa. Note that 6E10 also recognizes the Ab epitope in APP (top band), which was not increased in AD1. When the total protein content in AD1 temporal cortex was diluted to 6.78 lg to normalize total Ab levels to those seen in the comparison AD cases, the higher molecular weight bands, though lighter, were still detected by 6E10 immunoblot analysis, indicating that the presence of these bands cannot be accounted for simply by the overall quantity of Ab in AD1 temporal cortex (data not shown)
In summary, we describe a case of neuropathologically confirmed AD with heavy cerebral b-amyloidosis yet negligible high-affinity PIB binding in cortical homogenates. On a mechanistic level, the presence of PIBrefractory Ab in a confirmed case of Alzheimer's disease implies the existence of molecular strains of Ab that could be functionally dissimilar with regard to the pathogenesis of AD [17] , similar to the heterogeneity of prion strains [3, 6] . In this light, PIB and other binding agents could serve as specific, early diagnostic tools that distinguish polymorphic AD phenotypes, as well as selective in vitro molecular probes for strain-like structural variants of multimeric Ab [17] . Until the prevalence of PIB-refractory Ab in senescent humans can be established, our findings Fig. 9 Immunoprecipitation/MALDI-TOF MS detection of Ab peptides in the temporal cortex of case AD1 and a comparison PIBsensitive AD case (AD12). By mass spectrometry, we detected substantially more individual Ab fragments in all cortical fractions of AD1 temporal cortex, as compared to three other AD cases (data from a representative AD case shown). Numerous C-terminally truncated peptides (Ab1-x) were seen in the buffer (TBS)-soluble extract, yet Ab42 was barely detectable. These same truncated peptides also were detected in SDS-soluble extract, along with Ab40 and Ab42. Nterminally truncated peptides (Abx-40 and Abx-42) and full-length Ab40 and Ab42 predominated in formic acid-solubilized fractions (FA 70% and 100%) from AD1 cortex. This pattern of N-and Cterminal-specific truncations in soluble and insoluble cortical fractions was not seen in the comparison AD cases or in a nondemented control case (not shown). The Ab fragments written in red were particularly abundant, while those in parentheses were just barely detectable. a-42: Immunoprecipitation with monoclonal antibody 12F4, specific to Abx-42; 4G8/6E10: Immunoprecipitation with two monoclonal antibodies, one to Ab17-24 (4G8) and one to Ab1-16 (6E10); TBS tris-buffered saline extract; SDS sodium dodecyl sulfatesoluble extract; FA formic acid-solubilized extract indicate that limited 11 C-PIB retention in PET images of suspected AD cases should be interpreted with caution.
